Auzmer Research — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$257,119	12
2024	Research	$327,208	11
2023	Research	$406,071	8
2022	Research	$266,434	12
2021	Research	$189,958	5
2020	Research	$9,070	4

Breakdown

Who paid Research payments · program years 2020–2025

AstraZeneca Pharmaceuticals LP $1,370,731 38 payments
Amgen Inc. $61,153 3 payments
AbbVie, Inc. $18,477 9 payments
Sanofi Pasteur Inc. $5,500 2 payments

Studies the money was for Research payments · program years 2020–2025

A 54 Week Treatment, Multicenter, Randomized, Double Blind, Double Dummy, Placebo and Active Controlled, Parallel Group Phase 2 Study to Assess the Efficacy and Safety of Brazikumab in Participants with Moderately to Severely Active Ulcerative Colitis $319,114 5 payments
COSMOS - A Phase IIa Randomized Double-blind Placebo-controlled Study to Evaluate the Safety Tolerability and Pharmacodynamics of AZD4831 in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) with Fibrosis $213,097 3 payments
This study seeks to evaluate the safety and efficacy of brazikumab versus placebo (Stage I) and versus an active comparator (Stage 2) in participants with moderately to severely active CD and will include assessments of clinical response as demonstrated by improvement of symptoms and colonic mucosal appearance as observed on endoscopy $166,929 6 payments
A Phase 2 Open-label, Long-term Extension Safety Study of Brazikumab in Participants with Moderately to Severely Active Ulcerative Colitis $163,787 6 payments
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Relative to Budesonide and Formoterol Fumarate MDI and Symbicort pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma $136,445 5 payments
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS $102,327 2 payments
a phase third,randomised,double blind,placebo controlled,eventdriven study to evaluate the effect of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on the risk of incident heart failure and cardiovascular death in participants with increased risk of reveloping heart failure $87,437 1 payment
An Open label Long term Extension Study of Brazikumab in Participants with Moderately to Severely Active Crohns Disease $71,776 5 payments
A Phase 2a Randomised Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of AZD4604 Twice Daily for Twelve Weeks in Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA $63,867 2 payments
P2 UC $61,134 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.